Piper Jaffray Starts CRISPR Therapeutics (CRSP) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall Street futures fall as oil, Treasury yields rise on Iran tensions
- Oil prices fall after hitting over one-month high; traders weigh supply risks
- Dell again lifts annual forecasts as AI demand powers record results
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- Berkshire’s Abel says data centers are energy opportunity
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- S&P Global shares rise on report of possible CapIQ spinoff
Citi Starts CRISPR Therapeutics (CRSP) at Neutral
November 15, 2016 7:41 AM ESTCiti initiated coverage on CRISPR Therapeutics (NASDAQ: CRSP) with a Neutral rating and a price target of $19.00.
For an analyst ratings summary and ratings history on CRISPR Therapeutics click here. For more ratings news on CRISPR Therapeutics click here.
Shares of CRISPR Therapeutics closed at $17.60 yesterday.
... MoreGuggenheim Starts CRISPR Therapeutics (CRSP) at Buy
November 14, 2016 7:56 AM ESTGuggenheim initiated coverage on CRISPR Therapeutics (NASDAQ: CRSP) with a Buy rating and a price target of $30.00.
For an analyst ratings summary and ratings history on CRISPR Therapeutics click here. For more ratings news on CRISPR Therapeutics click here.
Shares of CRISPR Therapeutics closed at $17.50 yesterday.
... More